These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 23815496)

  • 1. Cross-reactivities between human IgMs and the four serotypes of dengue virus as probed with artificial homodimers of domain-III from the envelope proteins.
    Zidane N; Dussart P; Bremand L; Bedouelle H
    BMC Infect Dis; 2013 Jul; 13():302. PubMed ID: 23815496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct and indirect interactions in the recognition between a cross-neutralizing antibody and the four serotypes of dengue virus.
    Lisova O; Belkadi L; Bedouelle H
    J Mol Recognit; 2014 Apr; 27(4):205-14. PubMed ID: 24591178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection.
    Weiskopf D; Angelo MA; Sidney J; Peters B; Shresta S; Sette A
    J Virol; 2014 Oct; 88(19):11383-94. PubMed ID: 25056881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
    Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thermodynamic stability of domain III from the envelope protein of flaviviruses and its improvement by molecular design.
    Zidane N; Dussart P; Bremand L; Villani ME; Bedouelle H
    Protein Eng Des Sel; 2013 Jun; 26(6):389-99. PubMed ID: 23479674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity.
    Messer WB; de Alwis R; Yount BL; Royal SR; Huynh JP; Smith SA; Crowe JE; Doranz BJ; Kahle KM; Pfaff JM; White LJ; Sariol CA; de Silva AM; Baric RS
    Proc Natl Acad Sci U S A; 2014 Feb; 111(5):1939-44. PubMed ID: 24385585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High performance dengue virus antigen-based serotyping-NS1-ELISA (plus): A simple alternative approach to identify dengue virus serotypes in acute dengue specimens.
    Prommool T; Sethanant P; Phaenthaisong N; Tangthawornchaikul N; Songjaeng A; Avirutnan P; Mairiang D; Luangaram P; Srisawat C; Kasinrerk W; Vasanawathana S; Sriruksa K; Limpitikul W; Malasit P; Puttikhunt C
    PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009065. PubMed ID: 33635874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
    Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
    Poddar A; Ramasamy V; Shukla R; Rajpoot RK; Arora U; Jain SK; Swaminathan S; Khanna N
    BMC Biotechnol; 2016 Jun; 16(1):50. PubMed ID: 27301568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus.
    Gromowski GD; Barrett ND; Barrett AD
    J Virol; 2008 Sep; 82(17):8828-37. PubMed ID: 18562544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes.
    Andrade DV; Katzelnick LC; Widman DG; Balmaseda A; de Silva AM; Baric RS; Harris E
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1.
    Messer WB; Yount BL; Royal SR; de Alwis R; Widman DG; Smith SA; Crowe JE; Pfaff JM; Kahle KM; Doranz BJ; Ibarra KD; Harris E; de Silva AM; Baric RS
    J Virol; 2016 May; 90(10):5090-5097. PubMed ID: 26962223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.
    VanBlargan LA; Mukherjee S; Dowd KA; Durbin AP; Whitehead SS; Pierson TC
    PLoS Pathog; 2013; 9(12):e1003761. PubMed ID: 24348242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of an Enzyme-Linked Immunosorbent Assay for Rapid Detection of Dengue Virus (DENV) NS1 and Differentiation of DENV Serotypes during Early Infection.
    Lai SC; Huang YY; Shu PY; Chang SF; Hsieh PS; Wey JJ; Tsai MH; Ben RJ; Hsu YM; Fang YC; Hsiao ML; Lin CC
    J Clin Microbiol; 2019 Jul; 57(7):. PubMed ID: 30971466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.
    Priyamvada L; Cho A; Onlamoon N; Zheng NY; Huang M; Kovalenkov Y; Chokephaibulkit K; Angkasekwinai N; Pattanapanyasat K; Ahmed R; Wilson PC; Wrammert J
    J Virol; 2016 Jun; 90(12):5574-85. PubMed ID: 27030262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
    Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY
    J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody.
    Wahala WM; Kraus AA; Haymore LB; Accavitti-Loper MA; de Silva AM
    Virology; 2009 Sep; 392(1):103-13. PubMed ID: 19631955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An in-depth analysis of original antigenic sin in dengue virus infection.
    Midgley CM; Bajwa-Joseph M; Vasanawathana S; Limpitikul W; Wills B; Flanagan A; Waiyaiya E; Tran HB; Cowper AE; Chotiyarnwong P; Grimes JM; Yoksan S; Malasit P; Simmons CP; Mongkolsapaya J; Screaton GR
    J Virol; 2011 Jan; 85(1):410-21. PubMed ID: 20980526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones.
    Smith SA; de Alwis AR; Kose N; Jadi RS; de Silva AM; Crowe JE
    J Virol; 2014 Nov; 88(21):12233-41. PubMed ID: 25100837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural and biophysical analysis of sero-specific immune responses using epitope grafted Dengue ED3 mutants.
    Kulkarni MR; Islam MM; Numoto N; Elahi M; Mahib MR; Ito N; Kuroda Y
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1438-43. PubMed ID: 26160751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.